SCHEMBL4505864

SCHEMBL4505864

CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccccc3CNC(=O)Nc3cc(C(C)(C)C)nn3-c3cccc(OCCO)c3)c(Cl)c2=O)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 19/20 0.43
MAPK11 Q15759 4/20 0.41
MAPK12 P53778 3/20 0.41
ROCK2 O75116 1/20 0.41
STRADA Q7RTN6 1/20 0.41
CDK8 P49336 4/20 0.41
PKN2 Q16513 3/20 0.41
MAPK9 P45984 3/20 0.41
RET P07949 2/20 0.41
PDGFRA P16234 2/20 0.41
MAPK13 O15264 2/20 0.40
FLT1 P17948 2/20 0.37
MINK1 Q8N4C8 1/20 0.37
RAF1 P04049 1/20 0.37
PDGFRB P09619 1/20 0.37
KIT P10721 1/20 0.37
FGFR1 P11362 1/20 0.37
BRAF P15056 1/20 0.37
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4506806 0.95 MAPK14 (0.44) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL4508389 0.94 MAPK14 (0.44) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL13678590 0.94 MAPK14 (0.45) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL4499671 0.94 MAPK14 (0.43) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL13678591 0.93 MAPK14 (0.43) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL4498194 0.92 MAPK14 (0.40) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL13678566 0.92 MAPK14 (0.48) MAPK14MAPK11MAPK12ROCK2STRADA
SCHEMBL4520556 0.92 MAPK14 (0.41) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL13678613 0.91 MAPK14 (0.44) MAPK14MAPK11MAPK12CDK8PKN2
SCHEMBL4515766 0.90 MAPK14 (0.41) MAPK14MAPK11MAPK12CDK8PKN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US claimed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PFIZER INC. 2009-10-29 US disclosed
EP-1987022-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES Pfizer Products Inc. (US) 2008-11-05 EP disclosed
WO-2007091176-A1 PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270350-A1 Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives PDXK, UMPS, CDK2 MAPK14 117/4885MAPK11 404/4885MAPK12 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.